Brief: Cinclus Pharma Says FDA Clarifies Pivotal Study
23/02/2026 07:04
Feb 23 (Reuters) - Cinclus Pharma Holding publ AB CINPHA.ST: FDA CLARIFIES ONE PIVOTAL STUDY SUFFICIENT FOR DRUG APPROVAL IN USA PHASE III PROGRAM SUFFICIENT FOR US APPLICATION Source text: ID:nMFN3L1ZvG Further company coverage: CINPHA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))